WallStSmart

Abbott Laboratories (ABT)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 4279% more annual revenue ($45.13B vs $1.03B). ABT leads profitability with a 13.9% profit margin vs -3.7%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LMRI

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 7/9Altman Z: 0.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for LMRI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

LMRI1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

LMRI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
3.1%4/10

3.1% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$816.69M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : LMRI

The strongest argument for LMRI centers on Price/Book.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : LMRI

The primary concerns for LMRI are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.61 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while LMRI is a turnaround play — different risk/reward profiles.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Lumexa Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.

Want to dig deeper into these stocks?